What the FDA labels say about taking them together
Medroxyprogesterone and testosterone
Medroxyprogesterone's FDA label (Depo-Provera) of August 25, 2026 names testosterone in its drug interactions section; the testosterone labels PlainMeds reads (4) do not name medroxyprogesterone. The medroxyprogesterone label: “The following laboratory tests may be affected by progestins including Depo-Provera CI: (a) Plasma and urinary steroid levels are decreased. (b) Gonadotropin levels are decreased. …”
Check it at the source: the medroxyprogesterone FDA label on DailyMed (effective June 29, 2026, Pharmacia & Upjohn Company LLC); the testosterone FDA label on DailyMed (effective July 25, 2025, Azurity Pharmaceuticals, Inc.).
What does the medroxyprogesterone label say about testosterone?
Depo-Provera label (Pharmacia & Upjohn Company LLC, August 25, 2026), drug interactionsThe following laboratory tests may be affected by progestins including Depo-Provera CI: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (b) Gonadotropin levels are decreased. (c) Sex-hormone-binding-globulin concentrations are decreased. (d) Protein-bound iodine and butanol extractable protein-bound iodine may increase.
Source: FDA drug label (Depo-Provera, NDA020246), Pharmacia & Upjohn Company LLC, effective August 25, 2026 (SPL set 199cf13e-0859-4a73-9b45-e700d0cd1049), via openFDA
Source: FDA drug label (Provera), NDA011839 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective June 29, 2026 (SPL set a586be28-96af-4fed-a13f-9b94fd4c7405), via openFDA; the full label on DailyMed
What does the testosterone label say about medroxyprogesterone?
Testosterone's label (effective July 25, 2025) and its 3 other brand-application labels do not name medroxyprogesterone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AZMIRO), Azurity Pharmaceuticals, Inc., effective July 25, 2025 (SPL set 235b5625-570d-3fba-e063-6394a90aa2d1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Medroxyprogesterone | Testosterone | |
|---|---|---|
| Labeled for | Birth control, Pain | Breast cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $22.85 per mL 150 mg/mL | $11.39 per mL 200 mg/mL |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once